To Evaluate the Efficacy and Safety of HL151 Versus Placebo in Perennial Allergic Rhinitis Patients

NCT03655210 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

272

Enrollment

INDUSTRY

Sponsor class

Conditions

Perennial Allergic Rhinitis

Interventions

DRUG: HL151
DRUG: placebo

Sponsor

Hanlim Pharm. Co., Ltd.